-
Fomivirsen (brand name Vitravene) is an
antisense antiviral drug that was used in the
treatment of
cytomegalovirus retinitis (CMV) in immunocompromised...
- subsidiary,
Akcea Therapeutics. The company's
first marketed drug was
fomivirsen (Vitravene, used to
treat cytomegalovirus retinitis (CMV) in immunocompromised...
-
Administration (FDA) has
approved the
phosphorothioate antisense oligonucleotides fomivirsen (Vitravene) and
mipomersen (Kynamro) for
human therapeutic use. In virology...
- (Intelence) HIV
NNRTI 2008
Famciclovir Herpes Zoster Guanosine analogue 1994
Fomivirsen AIDS Anti-sense
oligonucleotide Anti-sense FDA-licensed in 1998 Withdrawn...
-
Follutein Folvite Folvron fomepizole (INN)
fomidacillin (INN)
fominoben (INN)
fomivirsen (INN)
fomocaine (INN)
fondaparinux sodium (USAN)
fontolizumab (INN) fonturacetam...
-
example of
individualized genomic medicine therapeutical intervention.
Fomivirsen (marketed as Vitravene), was
approved by the U.S. FDA in
August 1998,...
- the
operation of
those genomes. A
phosphorothioate antisense drug
named fomivirsen has been introduced, used to
treat opportunistic eye
infections in AIDS...
-
These compounds are the
basis of
antisense therapy, e.g., the
drugs fomivirsen (Vitravene), oblimersen, alicaforsen, and
mipomersen (Kynamro). Further...
-
asRNAs as drug candidates. In 1998, the
first asRNA drug,
fomivirsen, was
approved by FDA.
Fomivirsen, a 21 base-pair oligonucleotide, was
developed to treat...
- targets, the
cancer cells. The
first commercialized ADCs were Isis's
Fomivirsen and, more recently, Pfizer's (formerly Wyeth)
Mylotarg (gemtuzumab ozogamicin)...
